CagriSema Setback Triggers JPMorgan Downgrade as UBT251 Delivers 19.7% Weight Loss
JPMorgan downgraded Novo Nordisk following underwhelming CagriSema obesity trial results, triggering a stock dip. Meanwhile, its GLP-1/GIP/glucagon triple agonist UBT251 achieved a statistically significant mean weight loss of 19.7% after 24 weeks, highlighting potential pipeline upside despite near-term setbacks.
1. JPMorgan Downgrade Over CagriSema Trial Results
JPMorgan analysts downgraded Novo Nordisk following underwhelming results from its CagriSema obesity trial, citing weight-loss outcomes below expectations and potential regulatory challenges for the compound.
2. UBT251 Trial Shows 19.7% Mean Weight Loss
UBT251, a GLP-1/GIP/glucagon triple agonist co-developed with United Biotechnology, achieved a statistically significant mean weight loss of 19.7% after 24 weeks, highlighting a promising addition to Novo Nordisk’s obesity pipeline.
3. Market Reaction and Valuation Implications
The downgrade prompted an immediate decline in Novo Nordisk shares, while the UBT251 efficacy data has provided investors with potential long-term upside, contingent on successful future trial and approval milestones.